本帖最后由 老马 于 2012-1-13 21:20 编辑 3 }4 W3 Z v2 w2 x$ Z
' u. U/ n4 X% T/ ^/ W$ x
爱必妥和阿瓦斯丁的比较
( X+ r9 N% d$ Z" l6 c
2 x }$ e5 R2 c1 Y
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
# D1 O3 O9 K4 V. t4 h' J
) d+ ~( |! _, L9 j& u. h! B
: [0 h! P+ L# N) k, v
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
: d! u s; K S/ b0 P* w==================================================
3 W l. t0 W; NOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)! N y/ w6 Q# H2 [
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.+ O8 c% E% l) T
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.% a& E) P" J# \/ d |
|